SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in a broad selloff across AI neocloud stocks, as traders debate whether debt, rising financing costs and uncertain returns on data-center investment threaten the sectors business model. Some see the drop as an oversold pullback and argue Nebius is better positioned financially than peers, pointing to analyst support and insider buying; others expect further declines and question whether the rebound can last.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Goldman Sachs upgrade of CoreWeave to Buy is fueling a rebound debate after a steep selloff tied to concerns about the companys debt burden, borrowing costs, and financing needs. Bullish traders view the upgrade and AI demand as support for recovery, while skeptics argue that credit-market stress and heavy leverage remain serious risks.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs REGAL Phase 3 AML trial dominates discussion: the last disclosed count was 78 of the 80 deaths needed to trigger final analysis, and traders debate whether the prolonged wait signals longer survival or reflects uncertainty and trial risk. Speculation about an ASH disclosure and frustration with company silence contrast with calls to wait for confirmed results; SLS009 data is a secondary catalyst being watched.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

WULF is caught in a sharp AI-infrastructure selloff as traders weigh financing and leverage risks, higher-rate concerns, and bearish sector commentary against the companys contracted data-center business. A high-volume rebound and CEO interview distinguishing its powered-shell model from GPU-owning peers, alongside Morgan Stanleys bullish view, prompted debate over whether the selloff was overdone or reflects persistent execution and funding risks.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is caught in a broad selloff in AI data-center stocks as traders reassess heavy borrowing needs, financing costs and exposure to CoreWeaves credit concerns. Bulls cite the companys contracted backlog, buildout progress and recent executive share purchases, while skeptics worry that debt, dilution and funding risks could outweigh those strengths.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs stronger-than-expected third-quarter profitability and upbeat 2027 outlook are driving attention, despite revenue coming in slightly below expectations. Bulls are celebrating the operating improvement and speculating about a short squeeze, while skeptics question whether higher steel prices can overcome the companys debt burden.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Traders are reacting to EyePoints reported decision to end its pivotal wet-AMD trials and cut its workforce, with debate over whether that reduces competition for Ocular Therapeutix or reflects broader doubts about the retinal-drug market. Attention also remains on Axpaxlis regulatory path and the anticipated NDA filing.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

The FDA accepted CorMedixs supplemental REZZAYO application for priority review to expand use into preventing invasive fungal disease in transplant patients, with a target decision date in Q1 2027. Traders see the faster review and potential new indication as a growth catalyst, while noting that filing acceptance does not guarantee approval.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobiles announcement that Deutsche Telekom, Orange, Telefnica and Vodafone signed a letter of intent to explore a joint European satellite-spectrum bid is drawing attention, with traders viewing AST as a possible satellite partner. No provider has been selected, and optimism about the opportunity is tempered by concerns over launch timing, execution and the stocks steep decline.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Rumbles sharp selloff is driving attention, with traders debating whether the reported Anthropic cloud-computing deal can be financed and delivered, and whether future funding could dilute shareholders. Bears cite uncertainty around the deal, managements silence, and weakness across AI infrastructure stocks; bulls point to heavy short interest and the upcoming earnings report as potential counterweights.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HUTCHMED (China) Reports H1 2026 Results: Full Earnings Call Transcript

HUTCHMED (China) (NASDAQ:HCM) released quarterly financial results and hosted an earnings call on Thursday. Read the complete transcript below.
This transcript is brought to you by Benzinga APIs. For real-time access toread more...

AZN Ends NSCLC Study for Bispecific Antibody Over Unlikely Success

AstraZeneca halts a phase III NSCLC study for volrustomig after data show that the regimen is unlikely to meet key survival goals, while other lung cancer trials shine.

Why HUTCHMED (China) Limited (HCM) Is Gaining Attention After China Biotech Re-Rating

Why HUTCHMED (China) Limited (HCM) Is Gaining Attention After China Biotech Re-Rating...

HUTCHMED (NASDAQ:HCM) Hits New 52-Week Low  - What's Next?

HUTCHMED (NASDAQ:HCM) Hits New 12-Month Low - What's Next...

HUTCHMED Highlights $1.4B Liquidity, 2026 Revenue Outlook, and SAFFRON Catalyst at DB Conference

HUTCHMED (NASDAQ:HCM) executives highlighted 2025 financial results, commercial momentum for its marketed oncology portfolio, and upcoming clinical and regulatory catalysts during a presentation at...

HUTCHMED (NASDAQ:HCM) Shares Gap Down - Here's Why

HUTCHMED (NASDAQ:HCM) Shares Gap Down - Here's Why...

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Given Average Rating of "Hold" by Analysts

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM - Get Free Report) has been given an average rating of "Hold" by the six ratings firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold...

Short Interest in HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Decreases By 13.7%

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM - Get Free Report) saw a large decrease in short interest during the month of March. As of March 13th, there was short interest totaling 278,317 shares, a decrease of 13.7% from the February 26th total of 322,619 shares. Currently, 0.2% of the...

HUTCHMED (NASDAQ:HCM) Shares Gap Up   - Time to Buy?

HUTCHMED (NASDAQ:HCM) Shares Gap Up - Time to Buy...

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Consensus Recommendation of "Hold" from Brokerages

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM - Get Free Report) has been given a consensus rating of "Hold" by the six ratings firms that are presently covering the stock, Marketbeat Ratings...

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The Other Ventures segment involves the other commercial businesses which include the sales, marketing, manufacture, and distribution of prescription drugs and healthcare products. The company was founded on December 18, 2000 and is headquartered in Hong Kong.

HUTCHMED (China) Limited - ADR

Hutchmed Stock Hits Over One-Month High After China Accepts Kidney Cancer NDA Filed With Partner Innovent Biologics

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$14.05
Prev Close	$13.94
Open	$14.15
Dividend Yield	0.00%
50-Day Moving Average	$13.34
Beta	0.89
Avg. Volume	92,153.16
PE Ratio	138.15

52-Week High	$16.33
52-Week Low	$9.77
Market Capitalization	$2.45B
EPS (Annual)	$2.62
Price to Book	1.94
Revenue Per Employee	$306,215.29

Feed

News

Sentiment

Earnings

Fundamentals

Info

HCM Fundamentals